VC/PE/M&A. Healthcare Weekly(2018.01.31)

 Wed Jan 31 15:45:10 CST 2018 A- A+



  • 医美之风越吹越劲,Bonti获得1550万美元融资!
  • 前路漫漫,是喜是忧?CAR-T领先公司Juno Therapeutics被Celgene出价97亿美元收购。
  • 当完卖家当买家!LivaNova完成对ImThera的2.25亿美元收购。
  • 叫板三藩,硬扛波屯!纽约终于下定决定要花5亿美元建立生物科技园区!

私募融资 & IPO

1. 医美之风越吹越劲,Bonti获得1550万美元C轮融资

概要:专注肉毒素研发及其医疗和医美运用的初创公司Bonti近期获得了1550万美元的C轮融资,City Hill Ventures领投。曾在肉毒素Botox巨头艾尔建(Allergan)任职的多名高管自立门户建成了这家公司,并推出了旗舰产品EB-001。这个产品和Botox类似,但是起效更快、作用时间也更短,非常适合术后及非手术性的肌肉骨骼疼痛管理使用。新筹得的资金将帮助公司完成EB-001的二期试验及第二阶段研究的展开,并支持市场营销和研究工作。


Helmed by former Allergan execs, Bonti bags $15M

Jan 24, 2018

Ex-Allergan executives have pulled in $15.5 million in series C funding for Bonti, a startup working on a new botulinum neurotoxin for both therapeutic and cosmetic uses. The new capital will carry the company’s lead asset, EB-001, botulinum neurotoxin serotype E, through the end of an ongoing phase 2 trial and allow the initiation and completion of a second phase 2 study, according to a statement. The funds will also support market research efforts. Botox, a botulinum neurotoxin serotype A, is used cosmetically but is also marketed for the treatment of overactive bladder and chronic migraine, among other conditions. Bonti’s candidate works similarly to Botox, but it acts more quickly and its effects don’t last as long—the effects of EB-001 appear within 24 hours and last about three to four weeks, compared to onset of action between three and seven days and a duration of effect of about three to four months. These properties may make EB-001 “well-suited” for applications such as the treatment of postsurgical and nonsurgical musculoskeletal pain, the company said. “There remains an urgency to find novel, non-narcotic alternatives to treat pain to help combat the devastating opioid epidemic raging in the United States currently,” said Jonathan Lim, M.D., chairman and co-founder of Bonti and managing partner of City Hill Ventures, which led the round.

Source: FierceBiotech


1. 前路漫漫,是喜是忧?CAR-T领先公司Juno Therapeutics被Celgene出价97亿美元收购

概要:在努力从前几次CAR-T试验的挫败中回过神之后,Juno Therapeutics的CEO Hans Bishop已经接受了这个事实:公司将被Celgene收购,而他本人也将获得超过2亿美元的收入。不计算其他收入来源的话,截至上上周,Bishop在公司占250万股,如果按照每股87美元计算的话,他的持股将达到大约2.17亿美元。就像当前很多CAR-T公司一样,对于Bishop和Juno来说,未来的前途并不明确。Juno曾经是CAR-T领域的领先者,但是在临床试验出现死亡案例之后,它不得不恢复原状,并放弃其领先药物。不过Juno现在仍然是CAR-T市场上少有的可以吸引到类似这次Celgene的97亿美元投资的公司。如果这笔交易在本季度末最终正式完成的话,Bishop将成为医药公司并购交易后获得个人资金最高的几位CEO之一。


Juno Therapeutics CEO Bishop set for $200M+ payday with Celgene buyout

Jan 22, 2018

After working to recover from several CAR-T clinical setbacks, Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company sells itself to Celgene. Bishop, one of Juno's founders, is set to collect more than $200 million from the deal. As of last week, he held about 2.5 million shares, according to Nasdaq. At the $87-per-share price Celgene agreed to pay, his holdings are worth about $217 million. Other components of Bishop's pay package will likely boost the figure higher. As with other CAR-T players, the road hasn't always been certain for Bishop and Juno. The company was once a leader in the field before trial deaths set it back and forced it to abandon its lead drug. Still, Juno is among a few players near or on the market in CAR-T and attracted a $9.7 billion offer from Celgene on Monday. As of now, Novartis and Gilead remain the only companies with marketed CAR-T drugs. Novartis beat all other players to the market in CAR-T in August when the FDA signed off on Kymriah to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The company is now working to expand its med's reach in relapsed/refractory diffuse large B-cell lymphoma and in Europe to treat r/r ALL. Since Novartis' approval, Gilead picked up approval for Yescarta to treat certain types of large B-cell lymphoma. That drugmaker entered the field through its $11.9 billion Kite Pharma buyout in August. CAR-T meds are one-time treatments made of cells that are collected from each patient, re-engineered and then infused back into the patient to attack cancer. Given that drugmakers essentially sell them only once per patient, they are tagging them with premium prices. Novartis' Kymriah costs $475,000 with a reimbursement system in place if certain patients don't respond within a month, while Gilead's med costs $373,000. Even with their high prices, many experts see CAR-T drugs as a future cornerstone of cancer treatment. The windfall for Bishop, a Juno co-founder and its CEO since the company's 2013 creation, stands to be among pharma's largest if the buyout closes as expected this quarter. It remains to be seen just how large the golden parachute will grow to be once all of its components are included, but it will be tough to match Kite CEO Arie Belldegrun's $600-plus million payout following the Gilead deal. Last year, Medivation CEO David Hung made $354 million after his company's sale to Pfizer, including vested and unvested stock options, incentive plans and more. Before that, Allergan CEO David Pyott collected $100 million after his company's sale to Actavis. Wyeth CEO Bernard Poussot made $53 million following his company's sale to Pfizer, according to FiercePharma research, while Schering-Plough CEO Fred Hassan pocketed nearly $50 million from the Merck & Co merger.

Source: FiercePharma

2. 当完卖家当买家,爽!LivaNova完成对ImThera的2.25亿美元收购

概要:LivaNova近期完成了对ImThera Medical及其植入式睡眠呼吸暂停疗法的2.25亿美元的收购。ImThera位于美国加州圣迭戈,其旗舰产品为Aura6000,这是一种植入式舌下神经刺激器,通过一对分别位于锁骨和上颈部的植入式部件来刺激舌部肌肉,从而更好地控制上呼吸道气流、减轻睡眠呼吸暂停问题。这一设备于2014年11月获得了研究器械豁免,从而顺利进入了关键性临床试验。


UPDATE: LivaNova closes $225m ImThera buyout

Jan 23, 2018

LivaNova (NSDQ:LIVN) closed the $225 million buyout of ImThera Medical and its implantable sleep apnea treatment, according to an SEC filing from the company. San Diego-based ImThera’s flagship product is the Aura6000, an implanted hypoglossal nerve stimulator that uses a pair of implanted components, one near the collarbone and one in the upper neck, to stimulate tongue muscles to help control upper airway flow and reduce or eliminate sleep apnea. The device won FDA investigational device exemption in November 2014 for a pivotal trial. LivaNova, already in investor in ImThera, paid $78 million up front to acquire the rest of the company, with the remaining $147 million due on regulatory and sales milestones. The deal was originally announced last December, with LivaNova saying that the deal was expected to deliver “near-term” accretion. Earlier this month LivaNova, formed by the $2.7 billion merger of Italy’s Sorin and Cyberonics in October 2015, inked a deal to sell its cardiac rhythm management business to China’s MicroPort Scientific (HK:00853) for $190 million in cash.

Source: MassDevice


1. 叫板三藩,硬扛波屯!纽约终于下定决定要花5亿美元建立生物科技园区



New York sketches out $500M plan to build a biotech hub

Jan 23, 2018

New York City is doubling down on its long-discussed, never-realized dream of building a biotech hub to rival South San Francisco and Boston. The latest iteration of the dream comes backed by a $500 million financing package and a goal to quadruple the amount of R&D space in the city. City officials sketched out the funding that is available as part of a request for proposals about how to increase the amount of life science space on the rental market. The centerpiece of the plan is a $100 million investment by the city in a life science campus. Officials envisage the site serving as an institutional anchor for the New York biotech community while also providing a space for entrepreneurial training and R&D partnerships. Key details such as the location of the campus are yet to be nailed down.

Other facets of the plan are also light on specifics, but the city has a broad vision for how to address the bottlenecks that have constrained growth of the local biotech sector to date. Notably, the city is offering $300 million in tax incentives to encourage investment in commercial lab space. These tax breaks will carry the burden of addressing the long-standing shortage of space for biotech startups in New York City.

The focus of the spending reflects the city’s awareness of its own shortcomings. “One area where we know that we are not the top is in the commercialization of the life sciences," James Patchett, CEO of the New York City Economic Development Corporation, told Forbes. “And, so, we believe that there's a moment in time, right now, where if we put our cards on the table we can be a leader in this field.” Half of the remaining $100 million of the financing package is earmarked for investment in nonprofit research facilities. These investments are intended to help New York City’s existing institutions create spaces where their research can advance toward commercialization. In doing so, the city aims to build a bridge between academic researchers and the commercial lab space it hopes to bring online in the coming years. The